Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time

Ledesma, María Mora González López; Sánchez, Lautaro; Ojeda, Diego S.; Rouco, Santiago Oviedo; Rossi, A.; Varese, Augusto; Mazzitelli, Ignacio; Pascuale, Carla A.; Miglietta, Esteban A.; Rodríguez, Pamela; Pallarés, Horacio M.; Navarro, Guadalupe S. Costa; Caramelo, Julio J.; Rothlauf, Paul W.; Liu, Zhuoming; Bloyet, Louis-Marie; Pontelli, Marjorie Cornejo; Rasetto, Natali B.; Wenker, Shirley D.; Ramis, Lila Y.; Bialer, Magalí G.; Leone, María José de; Hernando, Carlos Esteban; Bianchimano, Luciana; Ríos, Antonella S.; Cienfuegos, María Soledad Treffinger; Rodriguez, Pamela Elizabeth; Longueira, Yésica; Laufer, Natalia; Álvarez, Diego E.; Ceballos, Ana; Ochoa, Valeria; Monzani, Cecilia; Turk, Gariela; Salvatori, Melina; Carradori, Jorge; Prost, Katherine; Rima, Alejandra; Varela, Claudia; Ercole, Regina; Toro, Rosana; Gutiérrez, Sebastián; Zubieta, Martín; Acuña, Dolores; Jodar, Mercedes Soledad Nabaes; Torres, Carolina; Mojsiejczuk, Laura; Viegas, Mariana; Velazquez, Pilar; Testa, Clarisa; Kreplak, Nicolás; Yanovsky, Marcelo J.; Whelan, Sean P. J.; Geffner, Jorge; Pífano, Marina; Gamarnik, Andrea V.

doi:10.1128/mbio.03442-21

Cited by 22 publications

(25 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with previous results reported for Sputnik V ( 14 ) and others ( 42 ), we observed a progressive waning in specific antibody titers up to 6 months after immunisation. Particularly, Oviedo-Rouco and collaborators ( 43 ) showed that antibody levels in older adults with a homologous scheme for BBIBP-CorV decrease significantly from 21 up to 220 days post vaccination.…”

Section: Discussionsupporting

confidence: 93%

“…The study evaluated 851 nursing home residents that received one of the following homologous vaccine platforms: Sputnik V (n=522), BBIBP-CorV (n=165) or AZD1222 (n=164); of the initial cohort, 693 participants reached the end of the follow-up (18.6% loss). The immune response was evaluated by measuring IgG anti-Spike titers using a well-established ELISA test ( 12 ) and neutralising capacity against a VSV-Spike pseudotyped virus ( 14 ), as well as against live ancestral B.1 and Omicron SARS-CoV-2 strains. General information about participants enrolled in this cohort, including gender, age, previous exposure to SARS-CoV-2 and comorbidities by vaccine is listed in Table 1 .…”

Section: Resultsmentioning

confidence: 99%

“…Plasma samples were heat inactivated at 56°C for 30 min. Serial dilutions of the plasma samples were pre-incubated with the VSV-Spike pseudotyped virus (CoV2pp-GFP, ancestral SARS-CoV-2 lineage B.1) ( 13 ) for 1 hour at 37°C, and then with cultured VERO cells for 24 hs, according to ( 14 ). Neutralisation assays were performed in biological duplicates.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Humoral response and neutralising capacity at 6 months post-vaccination against COVID-19 among institutionalised older adults in Argentina

Rodríguez

Silva²,

Miglietta³

et al. 2022

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

The COVID-19 pandemic has particularly affected older adults residing in nursing homes, resulting in high rates of hospitalisation and death. Here, we evaluated the longitudinal humoral response and neutralising capacity in plasma samples of volunteers vaccinated with different platforms (Sputnik V, BBIBP-CorV, and AZD1222). A cohort of 851 participants, mean age 83 (60-103 years), from the province of Buenos Aires, Argentina were included. Sequential plasma samples were taken at different time points after vaccination. After completing the vaccination schedule, infection-naïve volunteers who received either Sputnik V or AZD1222 exhibited significantly higher specific anti-Spike IgG titers than those who received BBIBP-CorV. Strong correlation between anti-Spike IgG titers and neutralising activity levels was evidenced at all times studied (rho=0.7 a 0.9). Previous exposure to SARS-CoV-2 and age <80 years were both associated with higher specific antibody levels. No differences in neutralising capacity were observed for the infection-naïve participants in either gender or age group. Similar to anti-Spike IgG titers, neutralising capacity decreased 3 to 9-fold at 6 months after initial vaccination for all platforms. Neutralising capacity against Omicron was between 10-58 fold lower compared to ancestral B.1 for all vaccine platforms at 21 days post dose 2 and 180 days post dose 1. This work provides evidence about the humoral response and neutralising capacity elicited by vaccination of a vulnerable elderly population. This data could be useful for pandemic management in defining public health policies, highlighting the need to apply reinforcements after a complete vaccination schedule.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Humoral response and neutralising capacity at 6 months post-vaccination against COVID-19 among institutionalised older adults in Argentina

Rodríguez

Silva²,

Miglietta³

et al. 2022

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Elderly volunteers with detectable anti-RBD antibodies at baseline, developed higher antibody titers within 14 days of vaccination, similar to what has been shown before in younger individuals [19,[24][25][26][27]. These results emphasize the importance of administering, in elderly individuals, at least two doses of Gam-COVID-Vac in order to achieve a robust immune response, especially in individuals without a previous SARS-CoV-2 infection.…”

Section: Discussionsupporting

confidence: 85%

Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients

Tomas-Grau

Maldonado-Galdeano

López³

et al. 2022

Aging

View full text Add to dashboard Cite

The early sequencing of the SARS-CoV-2 viral genome allowed for a speedy development of effective vaccines against the virus. Nevertheless, age-related immunosenescence, the inability to mount strong immune responses, still represents a major obstacle. Here, in a group of 149 elderly volunteers (70-96 years old), evolution of the humoral immune response over time to Gam-COVID-Vac (Sputnik V), a vaccine based on heterologous recombinant adenovirus-26 (Ad26) and adenovirus-5 (Ad5) carrying the Spike genome, was analyzed by an anti-RBD ELISA. At 28 days post vaccination (dpv), a seroconversion rate of 91% was achieved, showing the importance of administering at least two doses of Gam-COVID-Vac to elicit a robust immune response, especially in elderly individuals without previous SARS-CoV-2 infection. Interestingly, IgG specific antibodies that reached their highest titers around 28 dpv (median = 740), persisted without significant decrease after 60 dpv (median = 650). After 90 dpv, IgG titers began to drop, and at 180 dpv only 44.7% of the elderly individuals remained with detectable anti-RBD IgG antibodies. No significant differences were observed in specific humoral immune responses between genders at early times point. However, at 60 dpv anti-RBD titers were more persistent in elderly females, and only dropped at 90 dpv (p < 0.0001). As expected, the highest antibodies titers were elicited in the youngest subgroup (70-74 years). Our results show that Gam-COVID-Vac was able to deal with the ageing of the immune system, eliciting a robust immune response in an elderly cohort, which lasted approximately 90 dpv at high levels, and protected against COVID-19.

show abstract

“…Considering previous studies indicating that antibody responses undergo a maturation process, 3 , 4 we analysed the serum neutralising activity over time against the omicron variant. To this aim, we assessed the neutralising activity elicited by the Sputnik V vaccine 5 using the original B.1 isolate and a local isolate of BA.1 omicron. For this analysis, we used 60 samples (20 samples per timepoint) with the highest neutralising GMT for the original B.1 virus.…”

mentioning

confidence: 99%

Antibody durability at 1 year after Sputnik V vaccination

Sánchez¹,

Rouco²,

Pífano³

et al. 2022

The Lancet Infectious Diseases

Self Cite

View full text Add to dashboard Cite

Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time

Abstract: Vaccines have been produced in record time for SARS-CoV-2, offering the possibility of halting the global pandemic. However, inequalities in vaccine accessibility in different regions of the world create a need to increase international cooperation.

Cited by 22 publications

References 15 publications

Humoral response and neutralising capacity at 6 months post-vaccination against COVID-19 among institutionalised older adults in Argentina

Humoral response and neutralising capacity at 6 months post-vaccination against COVID-19 among institutionalised older adults in Argentina

Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients

Antibody durability at 1 year after Sputnik V vaccination

Contact Info

Product

Resources

About